Management of NAFLD: a stage-based approach

Area of Science:

• Hepatology
• Internal Medicine
• Public Health

Background:

• Non-alcoholic fatty liver disease (NAFLD) is the most common liver condition in the USA, impacting approximately 30% of the population.
• NAFLD is linked to higher mortality rates from cardiovascular disease, cancer, and liver-related complications.
• Identifying high-risk NAFLD patients for targeted interventions is crucial due to the impracticality of universal screening.

Purpose of the Study:

• To identify key risk factors associated with NAFLD progression.
• To present a stage-based treatment strategy for NAFLD management.
• To guide therapeutic decisions based on disease severity and individual patient factors.

Main Methods:

• Review of current literature on NAFLD prevalence, risk factors, and treatment guidelines.
• Analysis of disease progression pathways in NAFLD and non-alcoholic steatohepatitis (NASH).
• Stratification of treatment approaches according to NAFLD disease stage and fibrosis presence.

Main Results:

• NASH patients, particularly those with fibrosis, face a higher risk of adverse outcomes.
• Lifestyle interventions are fundamental for all NAFLD patients, regardless of disease stage.
• Targeted therapies should be reserved for patients most likely to benefit, based on disease stage and comorbidities.

Conclusions:

• A personalized, stage-based treatment approach is essential for managing NAFLD effectively.
• Focusing on high-risk individuals, especially those with NASH and fibrosis, can optimize treatment outcomes.
• Understanding risk factors for progression is key to preventing adverse events in the NAFLD population.